Design of potent inhibitors of human β-secretase. Part 1
摘要:
We describe a novel series of potent inhibitors of human beta-secretase. These compounds possess the hydroxyethyl amine transition state isostere. A 2.5A crystal structure of inhibitor 32 bound to BACE is provided.
SULFAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND ITS PHARMACEUTICALLY ACCEPTABLE SALT
申请人:Kim Ki Young
公开号:US20140024636A1
公开(公告)日:2014-01-23
Provided is a sulfamide derivative having an adamantyl group represented by the following Formula 1, or a pharmaceutically acceptable salt thereof. The sulfamide derivative suppresses the activity of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), and is useful in the treatment of various diseases that are mediated by 11β-HSD1.
[EN] NITROGEN RING LINKED DEOXYURIDINE TRIPHOSPHATASE INHIBITORS<br/>[FR] INHIBITEURS DE DÉSOXYURIDINE TRIPHOSPHATASE LIÉS À UN CYCLE AZOTE
申请人:CV6 THERAPEUTICS NI LTD
公开号:WO2018098208A1
公开(公告)日:2018-05-31
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.
本文件提供了dUTPase抑制剂,包含此类化合物的组合物以及使用此类化合物和组合物的方法。
[EN] ISOPRENYL COMPOUNDS AND METHODS THEREOF<br/>[FR] COMPOSÉS ISOPRÉNYLÉS ET LEURS PROCÉDÉS
申请人:SIGNUM BIOSCIENCES INC
公开号:WO2010056778A1
公开(公告)日:2010-05-20
Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses.
Compounds of the formula: ##STR1## wherein R is aryl of 6 to 12 carbon atoms or aralkyl of 7 to 14 carbon atoms either optionally substituted with 1 to 3 substituents independently selected from lower alkyl of 1 to 6 carbon atoms, lower alkoxy of 1 to 6 carbon atoms, lower alkylthio of 1 to 6 carbon atoms, lower alkylsulfinyl of 1 to 6 carbon atoms, lower alkylsulfonyl of 1 to 6 carbon atoms, halogen, trihalomethyl, nitro, cyano or carboxyl; alkyl of 1 to 10 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, lower alkenyl of 2 to 6 carbon atoms, or lower alkynyl of 2 to 6 carbon atoms, all optionally substituted with 1 to 3 halogen atoms; lower alkoxyalkylene; lower alkylene carbalkoxy; lower alkylthioalkylene; lower alkylsulfinylalkylene; or lower alkylsulfonylalkylene; R.sup.1 and R.sup.2 are independently hydrogen, lower alkyl of 1 to 6 carbon atoms, aryl of 6 to 12 carbon atoms, or thienyl, or taken together form an alkylene bridge to give a cycloalkyl group of 3 to 10 carbon atoms; and R.sup.3 is alkyl of 1 to 3 carbon atoms substituted with 3 to 6 halogen atoms or trihalovinyl are fungicidal.
[EN] NOVEL COMPOUNDS AS MODULATORS OF GPR-119<br/>[FR] NOUVEAUX COMPOSES UTILISES COMME MODULATEURS DE GPR-119
申请人:RHIZEN PHARMACEUTICALS SA
公开号:WO2012170867A1
公开(公告)日:2012-12-13
The present invention relates to novel compounds of formula (A) and (B) as modulators of GPR-119, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of GPR-119 mediated diseases or disorders with them.